Protective effect of genistein on nonalcoholic fatty liver disease (NAFLD) - 31/07/19

Doi : 10.1016/j.biopha.2019.109047

Xin Xin ^a, Cheng Chen ^a, Yi-Yang Hu ^a,^b,^c, Qin Feng ^a,^b,^c,^⁎
^a Institute of Liver diseases, Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China
^b Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai, 201203, China
^c Key Laboratory of Liver and Kidney Diseases, Shanghai University of Traditional Chinese Medicine, Ministry of Education, Shanghai, 201203, China

^⁎Corresponding author.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

pages	11
Iconographies	3
Vidéos	0
Autres	0

Abstract

NAFLD is a vital health problem worldwide; however, no effective treatment is currently available for NAFLD. Intensive studies have indicated the efficacy of genistein (GE), a bioactive isoflavone extracted from soy, in treating NAFLD. In addition to its oestrogen-like effects, GE is known to have multiple molecular effects, for instance, lipid and glucose metabolism-promoting effects and activities against lipid peroxidation, inflammation, fibrosis, and NAFLD-related tumours. Here, this review summarizes the potential role of GE in the treatment and prevention of NAFLD and some of the currently known targets and signalling pathways of GE in NAFLD.

Le texte complet de cet article est disponible en PDF.

Abbreviations : GE, SP, NAFLD, NASH, SFLD, HCC, HFD, FFA, TG, TC, TAG, LDL-R, LDL-C, HDL, BMI, AMPK, Thr172, SREBPs, PPAR-γ, ACC, FAS